ADCendo is a biotech company founded in Copenhagen in 2017, focused on the development of novel targeted therapies for a selected number of bone, connective tissue and brain cancers, for which no targeted therapies currently exist.
ADCendo is founded on a basis of basic cancer research by the scientific founders, and a worldwide license to explore and commercialize certain inventions, made by the founders during their assignments at the Finsen Laboratory, relating to antibody drug conjugate drugs targeting the uPARAP receptor in a novel context. Inventions, which are based on decades of extensive research on the role of this particular receptor in cancer, as part of the laboratory’s basic research program.
The company name, ADCendo, reflects our particular focus on development of antibody-drug conjugates (ADCs) against cancer cell receptors with specialized endocytic properties.
The ADCendo team
The ADCendo team is comprised of experienced biotech entrepreneur Henrik Stage, acting as the company CEO, and a scientific team with world leading expertise in the biology of the target receptors based on decades of basic research at The Finsen Laboratory, a basic cancer research unit at Rigshospitalet.
CEO and co-founder Henrik Stage is an experienced biotech-entrepreneur, active in several biotech companies, and was previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014.
Henrik is partner at Ventac Partners.
CSO and co-founder Niels Behrendt is a Doctor of Science and PhD from the University of Copenhagen. He has been active in cancer research for more than 20 years and has particular expertise in the structure, function and targeting of receptors engaged in cancer invasion. He has longstanding experience in research leadership and has supervised a major part of the scientific work that enables the cancer targeting strategy of ADCendo.
CTO and co-founder Christoffer F. Nielsen got his PhD in nanomedicine from the iNANO center at Aarhus University in 2012, having worked on development of methods for antibody-mediated delivery of RNA-based medicine. He then moved to The Finsen Laboratory in Copenhagen, where he helped establish and since then carry out the scientific project on utilization of certain receptors for targeted drug delivery by ADCs, that would eventually form the scientific backbone of ADCendo.
COO and co-founder Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early in his career he focused on cancer research, and the continued work in this field has given him an extensive knowledge about cancer pathology and cancer models. The work with cancer models and studies on patient material has been a keystone to develop the targeting strategy used by ADCendo.
CRO Andreas Hald obtained his PhD from University of Copenhagen based on research in cancer biology and -treatment. In addition to extensive experience in academic research relating to inflammation, cancer, and tissue remodeling, he has been employed in both biotech and large pharma companies. In 2017 he joined the ADCendo team to strengthen the internal preclinical development program of ADCs.